Description: Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for glioblastoma and hematological or solid tumors. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden
Home Page: www.oncopeptides.com/sv
Luntmakargatan 46
Stockholm,
111 37
Sweden
Phone:
46 86 15 20 40
Officers
| Name | Title |
|---|---|
| Ms. Sofia Heigis M.Sc. | Chief Executive Officer |
| Dr. Jakob Lindberg Med. Lic | Chief Scientific Officer |
| Prof. Rolf Larsson M.D., Ph.D. | Founder |
| Prof. Rolf Lewensohn M.D., Ph.D. | Founder |
| Dr. Joachim Gullbo M.D., MSc Pharm, Ph.D. | Founder |
| Dr. Kristina Luthman Ph.D. | Founder |
| Prof. Hans Ehrsson M.D. | Founder |
| Mr. Peter Nygren | Founder |
| Mr. Henrik Bergentoft | Chief Financial Officer |
| Ms. Eva Nordström M.Sc., MSc Pharm | COO & Deputy MD |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.3625 |
| Price-to-Sales TTM: | 1.0301 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 79 |